The perfluorocarbon liquids (PFCLs) are synthetic liquid fluorinated carbon-containing compounds, first investigated and used as vitreous tamponade in the 1980s.
1,2 Physically PFCLs are characterized by specific gravity greater than water (ranging from 1.7–2.03 g/cm
3);
3 moderate interfacial tension (approximately 50 mN/m against water); and low viscosity, transparency, and immiscibility with water.
4 Due to the aforementioned properties, PFCLs unfold and keep the detached retina flat, concurrently with the anterior displacement of the subretinal fluid, allowing to perform other surgical maneuvers, such as membrane removal or photocoagulation.
5 Therefore, they are valid intraoperative tools for surgical treatment of complex retinal detachments (RDs), especially in the presence of severe proliferative vitreoretinopathy (PVR), giant retinal tears, funnel-shaped RDs, and proliferative diabetic retinopathy.
5,6 Moreover, PFCLs are used off-label for primary RDs, dropped lenses with or without RD, removal of foreign bodies, drainage of suprachoroidal hemorrhage, and management of submacular hemorrhage.
6,7 Despite the potential advantages of such high specific gravity, these compounds are not used as long-term tamponade because their persistence in the vitreous cavity has been associated with irreversible retinal toxicity, emulsification, and inflammation.
8,9 Therefore, careful removal of PFCL not only is crucial, but also challenging as we already reported describing the induced foreign body response consequent to intraoperative use of PFCL and the accumulation of residual droplets of PFCL 10 minutes after the air–fluid exchange.
10,11 Currently, the most largely used PFCLs are perfluorodecalin (PFD) and perfluoro-n-octane (PFO). In particular, PFO, as a saturated fluorinated compound, is considered chemically and biologically inert and its safe profile has been variously documented.
7,12,13 The safety of PFO and PFD, medical devices intended for intraocular use is an essential requirement according to European
14–16 and US regulations.
15–17 Nevertheless, recently Pastor et al.
18 reported 117 cases of severe retinal acute toxicity, mostly characterized by retinal necrosis and vascular occlusion, after intraoperative use of PFO Ala-Octa (Alamedics, Dornstadt, Germany). This PFO was certified as safe by a German company based on an extract cytotoxicity test.
15 Performing a counter-analysis of some unused toxic lots of PFO Ala-Octa, the Spanish Instituto de Oftalmobiología Aplicada (IOBA) determined their toxicity, identifying benzene derivatives, perfluorooctanoic acid and dodecafluoro-1-heptanol as suspected causative agents.
18 IOBA used human retinal pigment epithelial cells (ARPE-19 cells) in direct contact methods.
15,18 Showing their results, Pastor et al.
18 and Srivastava et al.
19 declaimed the failure and inadequacy of the ISO 10993-5 criteria and proposed a different protocol for the evaluation of cytotoxicity.